Personalized Medicine Genomas specializes in clinical pharmacogenetic testing to tailor prescription and dosing across a wide range of medications, indicating a sales opportunity to healthcare providers seeking precision medicine solutions and to health systems implementing pharmacogenomics programs.

Acquisition Backing As a division of Rennova Health, Genomas benefits from the backing of a publicly traded parent, suggesting credibility for partnerships and potential integration opportunities with Rennova’s diagnostics and software offerings.

Growing Market Footprint Recent history shows strategic acquisitions and partnerships, positioning Genomas within broader diagnostics and personalized medicine ecosystems, which can be leveraged to cross-sell pharmacogenetic testing alongside related lab services.

Tech Enablement Operational tech stack includes cloud infrastructure (AWS), web platforms, and development tools, presenting avenues to propose scalable, compliant data management, integration with electronic health records, and secure patient data workflows.

Revenue Build Current revenue is under one million, signaling a growth phase with room for expansion through enterprise contracts, provider networks, and collaboration with pharma or biotech partners interested in pharmacogenomics-enabled prescribing.